ES2055689T3 - Tableta para la segregacion mantenida de teofilina. - Google Patents

Tableta para la segregacion mantenida de teofilina.

Info

Publication number
ES2055689T3
ES2055689T3 ES87100888T ES87100888T ES2055689T3 ES 2055689 T3 ES2055689 T3 ES 2055689T3 ES 87100888 T ES87100888 T ES 87100888T ES 87100888 T ES87100888 T ES 87100888T ES 2055689 T3 ES2055689 T3 ES 2055689T3
Authority
ES
Spain
Prior art keywords
weight percent
theophylline
tablet
water
theophiline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87100888T
Other languages
English (en)
Inventor
Aracelis M Ortega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARVALSA AG
Original Assignee
FARVALSA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARVALSA AG filed Critical FARVALSA AG
Application granted granted Critical
Publication of ES2055689T3 publication Critical patent/ES2055689T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

SE DESCRIBEN PASTILLAS COMPRIMIDAS A PARTIR DE LAS CUALES SE LIBERA TEOFILINA A UNA VELOCIDAD CONSTANTE, CON INTERVALOS DE DOSIFICACION DE DOCE HORAS. LAS PASTILLAS CONTIENEN 43 A 50 % EN PESO DE TEOFILINA; 10 A 20 % EN PESO DE POLIMERO INSOLUBLE EN AGUA; 10 A 15 % EN PESO DE UN POLIMERO SELECCIONADO DEL GRUPO QUE CONSTA DE POLIMEROS SOLUBLES EN AGUA Y FORMADORES DE GEL HIDROFILOS QUE SE INCHAN EN EL AGUA; Y 5 A 15 % EN PESO DE POLIMERO INSOLUBLE EN ACIDO QUE TIENE GRUPOS CARBOXILICOS. LA PASTILLA PUEDE CONTENER ADEMAS 5 A 9 % EN PESO DE LUBRICANTE HIDROFOBO. UNA COMPOSICION PREFERIDA CONTIENE: 43 A 50 % EN PESO DE TEOFILINA; 10 A 20 % EN PESO DE ACETATO DE POLIVINILO; 10 A 15 % EN PESO DE POLIVINILPIRROLIDINA; 5 A 15 % EN PESO DE FTALATO ACETATO DE CELULOSA Y, OPCIONALMENTE, CONTIENE 5 A 7 % EN PESO DE UNA MEZCLA LUBRICANTE QUE CONTIENE ACIDO ESTEARICO, ESTEARATO DE MAGNESIO Y TALCO.
ES87100888T 1986-02-04 1987-01-23 Tableta para la segregacion mantenida de teofilina. Expired - Lifetime ES2055689T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/825,909 US4837032A (en) 1986-02-04 1986-02-04 Theophylline sustained release tablet

Publications (1)

Publication Number Publication Date
ES2055689T3 true ES2055689T3 (es) 1994-09-01

Family

ID=25245217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87100888T Expired - Lifetime ES2055689T3 (es) 1986-02-04 1987-01-23 Tableta para la segregacion mantenida de teofilina.

Country Status (8)

Country Link
US (1) US4837032A (es)
EP (1) EP0231826B1 (es)
JP (1) JPS6357523A (es)
AT (1) ATE69952T1 (es)
CA (1) CA1273876A (es)
DE (1) DE3774889D1 (es)
ES (1) ES2055689T3 (es)
GR (1) GR3003805T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521461B2 (ja) * 1987-03-10 1996-08-07 エスエス製薬株式会社 持続性錠剤
US4990335A (en) * 1987-03-25 1991-02-05 E. I. Du Pont De Nemours And Company Use of vinyl alcohol homopolymer and copolymers for tableting active materials
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
DE19709663A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
KR101697773B1 (ko) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. 독소필린을 포함하는 변형 방출 조성물
CN105101958B (zh) * 2013-01-15 2019-05-17 纽斯尔特科学公司 治疗肺病状
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809916A (en) * 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
US3062720A (en) * 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
NL297088A (es) * 1961-01-31
DE1467781A1 (de) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
DE2404257C3 (de) * 1974-01-30 1979-12-06 Ludwig Heumann & Co Gmbh, 8500 Nuernberg Verfahren zur Herstellung von Arzneimittelgranulaten mit Depotwirkung
JPS55153715A (en) * 1979-05-18 1980-11-29 Nikken Kagaku Kk Prolonged granule of theophylline
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
DE3435325A1 (de) * 1983-04-09 1986-04-17 Nikken Chemicals Co., Ltd., Tokio/Tokyo Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules

Also Published As

Publication number Publication date
DE3774889D1 (de) 1992-01-16
ATE69952T1 (de) 1991-12-15
EP0231826B1 (en) 1991-12-04
CA1273876A (en) 1990-09-11
JPS6357523A (ja) 1988-03-12
EP0231826A3 (en) 1987-12-02
US4837032A (en) 1989-06-06
GR3003805T3 (es) 1993-03-16
EP0231826A2 (en) 1987-08-12

Similar Documents

Publication Publication Date Title
ES2055689T3 (es) Tableta para la segregacion mantenida de teofilina.
GR80109B (en) Crosslinked porous polymers for controlled drug devivery
PT84188A (pt) Process for preparing a pharmaceutical composition for the obtention of an hydrogel or an highly viscose suspension
DK165458C (da) Farmaceutisk eller veterinaert acceptabel, amphipatisk, ikke-tvaerbundet, lineaer, forgrenet eller podeblokcopolymer og fremgangsmaade til fremstilling af denne,matrix til brug i et laegemiddel til frigivelse af syrestabile polypeptider omfattende copolymeren samt farmaceutisk middel til parenteral administration omfattende et farmakologisk nyttigt polypeptid og omfattende copolymeren
GR3005866T3 (es)
SG108191G (en) Copolymer and method for producing the same
GR3036586T3 (en) Novel hydrogels containing triblock copolymers, and preparation and use thereof
ES8201596A1 (es) Procedimiento de obtencion de mucopolisacaridos
DE3883505T2 (de) Biologisch aktive Systeme.
ATE63057T1 (de) Organophilen ton enthaltendes kompaktpulver sowie verfahren zu dessen herstellung.
ES2194832T3 (es) Formulaciones de ditiazem con absorcion controlada.
FR2598433B1 (fr) Procede de production d'interleukine-2 humaine, interleukine-2 ainsi obtenue, son utilisation a titre de medicament et composition pharmaceutique la contenant
ES526928A0 (es) Procedimiento de fabricacion de comprimidos de liberacion controlada
GR3017161T3 (en) Multi-fractionable tablet structure.
ATE1734T1 (de) Schmerzstillende tablette und verfahren zu deren herstellung.
PT87404A (pt) Process for the preparation of an additive for the fire extinction water containing high polymers
JPS5483989A (en) Preparation of hydrophilic polymer
BE894597A (fr) Nouvelles xanthines a activite pharmacologique, leur procede d'obtention, les compositions pharmaceutiques les contenant et leur utilisation en medecine humaine
BE898967A (fr) Medicament contenant de la muzolimine et son procede de preparation
JPS523677A (en) Process for polymerization of alpha-olefins
JPS5218786A (en) Suspension polymerization process of vinyl chloride
JPS5350288A (en) Preventin of stickiness of water-containing gel of acrylamide type polymer
JPS5218785A (en) Suspension polymerization process of vinyl chloride
JPS5667390A (en) Thermogenous composition
JPS53113879A (en) Suspension polymerization of vinyl chloride

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 231826

Country of ref document: ES